Autoimmune diseases

ChemoCentryx to Participate in the Canaccord Genuity 41st Annual Growth Conference

Retrieved on: 
Wednesday, August 4, 2021
Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Immunology, Canaccord Genuity, Autoimmune disease, Genuity, Sjögren syndrome, Autoimmunity

SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11 at 5:00 p.m.

Key Points: 
  • SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11 at 5:00 p.m.
  • A live audio webcast of the presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com.
  • ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer.
  • ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

AXIM® Biotechnologies to Acquire Technology Including Two FDA-Cleared 510(k)’s for Diagnostic Testing of Dry Eye Disease

Retrieved on: 
Tuesday, August 3, 2021
Medicine, Organ systems, Health, Autoimmune diseases, Dry eye syndrome, Sjögren syndrome, Visual acuity, Eye, Disease

The prevalence of Dry Eye Disease can significantly impair visual acuity, workplace productivity, and quality of life and increases with age.

Key Points: 
  • The prevalence of Dry Eye Disease can significantly impair visual acuity, workplace productivity, and quality of life and increases with age.
  • Dry Eye Disease is a common condition that occurs when your tears aren't able to provide adequate lubrication for your eyes.
  • Diagnosing Dry Eye Disease is a challenge because its a multifactorial disease with many disparate causes.
  • However, both are non-differential meaning they are screening tests that require follow-up testing because positive results could point to conditions other than Dry Eye Disease.

Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis

Retrieved on: 
Monday, August 2, 2021
Monoclonal antibodies, Medical specialties, Immunosuppressants, Life sciences, Natalizumab, Immunology, Multiple sclerosis, Biogen, Autoimmune diseases

The NOVA study provides the first prospective, randomized efficacy data of every six-week dosing with natalizumab, building on its well-established clinical profile and the real-world findings1,2,3, said Maha Radhakrishnan, M.D., Chief Medical Officer at Biogen.

Key Points: 
  • The NOVA study provides the first prospective, randomized efficacy data of every six-week dosing with natalizumab, building on its well-established clinical profile and the real-world findings1,2,3, said Maha Radhakrishnan, M.D., Chief Medical Officer at Biogen.
  • A complete analysis of the study data is ongoing and detailed results will be shared in a future scientific forum.
  • Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis.
  • No Difference in Radiologic Outcomes for Natalizumab Patients on Extended Interval Dosing Compared with Standard Interval Dosing in MS PATHS.

SAPHNELO (anifrolumab) Approved in the US for Moderate to Severe Systemic Lupus Erythematosus

Retrieved on: 
Monday, August 2, 2021
FDA, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Medical specialties, Autoimmune diseases, Clinical medicine, Medicine, Cutaneous lupus erythematosus, Connective tissue diseases, Lupus, William Osler, Syndromes, Anifrolumab, Sjögren syndrome, Rheumatology

AstraZenecas SAPHNELO (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.

Key Points: 
  • AstraZenecas SAPHNELO (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.
  • SAPHNELO is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy.
  • Limitations of Use: The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus.
  • The Companys growing presence in immunology is focused on five mid- to late-stage franchises with multi-disease potential, in areas including rheumatology (including systemic lupus erythematosus), dermatology, gastroenterology, and systemic eosinophilic-driven diseases.

Newly Approved Lupus Drug Based on Discoveries Made in HSS Lab

Retrieved on: 
Monday, August 2, 2021
Autoimmune diseases, Medical specialties, Clinical medicine, Medicine, Connective tissue diseases, Hospital for Special Surgery, NewYork–Presbyterian Healthcare System, Lupus, Sjögren syndrome, Immune system

Much of the groundwork for the development of this drug was done in laboratories at Hospital for Special Surgery (HSS) in the early 2000s.

Key Points: 
  • Much of the groundwork for the development of this drug was done in laboratories at Hospital for Special Surgery (HSS) in the early 2000s.
  • In lupus, however, this receptor is activated even when no infection is present, causing the immune system to instead attack its host.
  • In the lab, Dr. Crow and her team began studying the blood of people with lupus and comparing it to the blood of healthy individuals.
  • In 2003, Dr. Crow and her HSS team were one of three groups to publish research confirming interferon's pivotal role in lupus.

Lupus Foundation of America Celebrates FDA Approval of Saphnelo™ (Anifrolumab-fnia) as a New Treatment for Lupus

Retrieved on: 
Monday, August 2, 2021
Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Cutaneous lupus erythematosus, Connective tissue diseases, Lupus, William Osler, Autoimmune disease, Sjögren syndrome, Lupus erythematosus

It is the third U.S. FDA approval of a lupus therapy since 2011, expanding treatment options for this medically underserved and life-threatening autoimmune disease.

Key Points: 
  • It is the third U.S. FDA approval of a lupus therapy since 2011, expanding treatment options for this medically underserved and life-threatening autoimmune disease.
  • With the approval of Saphnelo, we now have one more drug that allows us to translate valuable research knowledge into clinical practice with multiple benefits for our patients with lupus."
  • Saphnelo showed benefits on overall lupus disease activity, skin lupus and joints and the ability to taper down steroid doses.
  • The Lupus Foundation of America's research during the 1980s contributed to the development of Saphnelo through its support of research on interferons.

Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca's anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)

Retrieved on: 
Monday, August 2, 2021
Medical specialties, Cutaneous lupus erythematosus, Medicine, Clinical medicine, Autoimmune diseases, Lupus, William Osler, Draft:Lupus UK, Lupus Foundation of America

Given by intravenous infusion, anifrolumab-fnia works by blocking immune system molecules called type I interferons that are one of the main factors that leads to tissue damage and disease symptoms. Type I interferons are a family of 17 similar molecules that help protect us from infections.i Research has shown that the vast majority -- 60-80 percent of adultsii -- have high levels of type I interferons.

Key Points: 
  • The approval represents the first new treatment for generalized SLE in more than a decade and is the result of significant seminal research funded originally by the Lupus Research Alliance.
  • One of the trailblazers in interferon research is former chair of the Lupus Research Alliance Scientific Advisory Board Dr. Mary Crow.
  • Over the past two decades, the Lupus Research Alliance has made significant investments in research focused on the role of type I interferons in lupus.
  • Because the Lupus Research Alliance's Board of Directors fund all administrative and fundraising costs, 100% of all donations goes to support lupus research programs.

Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca's anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)

Retrieved on: 
Monday, August 2, 2021
Medical specialties, Cutaneous lupus erythematosus, Medicine, Clinical medicine, Autoimmune diseases, Lupus, William Osler, Draft:Lupus UK, Lupus Foundation of America

Given by intravenous infusion, anifrolumab-fnia works by blocking immune system molecules called type I interferons that are one of the main factors that leads to tissue damage and disease symptoms. Type I interferons are a family of 17 similar molecules that help protect us from infections.i Research has shown that the vast majority -- 60-80 percent of adultsii -- have high levels of type I interferons.

Key Points: 
  • The approval represents the first new treatment for generalized SLE in more than a decade and is the result of significant seminal research funded originally by the Lupus Research Alliance.
  • One of the trailblazers in interferon research is former chair of the Lupus Research Alliance Scientific Advisory Board Dr. Mary Crow.
  • Over the past two decades, the Lupus Research Alliance has made significant investments in research focused on the role of type I interferons in lupus.
  • Because the Lupus Research Alliance's Board of Directors fund all administrative and fundraising costs, 100% of all donations goes to support lupus research programs.

aTyr Pharma Announces Grant of U.S. Patent for Use of Histidyl-tRNA Synthetase Fc Fusion Proteins for Reducing Inflammatory Response in the Lung

Retrieved on: 
Thursday, July 29, 2021
Protein biosynthesis, Autoimmune diseases, Lung disorders, Branches of biology, Histidine—tRNA ligase, Transfer RNA, Biology, Aminoacyl tRNA synthetase, Sarcoidosis, Chemistry, aTyr Pharma, Xiang-Lei Yang

11,072,787 entitled, Histidyl-tRNA synthetase-FC conjugates, covers the use of the companys lead therapeutic candidate, ATYR1923, for reducing inflammatory response in the lung.

Key Points: 
  • 11,072,787 entitled, Histidyl-tRNA synthetase-FC conjugates, covers the use of the companys lead therapeutic candidate, ATYR1923, for reducing inflammatory response in the lung.
  • ATYR1923 is a Fc fusion protein based on the N terminal fragment of histidyl-tRNA synthetase that is currently in clinical development for the treatment of pulmonary sarcoidosis and is being evaluated in other inflammatory lung diseases.
  • These patents encompassed important new therapeutic modalities which underpin the broad pipeline of novel therapeutics in active development at the company.
  • aTyr is developing ATYR1923 as a potential therapeutic for patients with inflammatory lung diseases.

Scipher Medicine Increases Patient Access for Prismra® by Expanding Intended Use in Autoimmune Patients

Retrieved on: 
Thursday, July 29, 2021
Medical specialties, Clinical medicine, Medicine, Rheumatology, Autoimmune diseases, Connective tissue diseases, Arthritis, Rheumatoid arthritis, Precision medicine, Sjögren syndrome, Autoimmunity, Lars Klareskog

WALTHAM, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with most effective therapy, today announced the expanded clinical utility and intended use to include most rheumatoid arthritis (RA) patients for its commercially available PrismRA blood test.

Key Points: 
  • WALTHAM, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with most effective therapy, today announced the expanded clinical utility and intended use to include most rheumatoid arthritis (RA) patients for its commercially available PrismRA blood test.
  • PrismRA is a first-of-its-kind molecular signature test that informs personalized treatment decisions for RA patients at any point in the clinical journey.
  • PrismRA, a molecular signature test, is a revolutionary advancement bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally.
  • We partner with payers, providers, and pharma along the healthcare value chain to bring precision medicine to autoimmune diseases.